New drug development is a high-risk venture, but if successful, will bring great revenues to those willing to accept the risk. In the field of urology, in particular for lower urinary tract symptoms (LUTS), the recent successful landing of drugs (e.g., mirabegron, botulinum toxin A, and tadalafil) has resulted in increased interest in new drug development. Benign prostatic hyperplasia and overactive bladder syndrome, representative LUTS diseases, are attractive targets because of their prevalence and market size in the field of urology. Additionally, the awareness about new stream of research is very important not only because of the market size and economic factors, but also because to keep steady attention to these research for the researcher's. We have reviewed a selection of new drugs currently under development for the treatment of the two aforementioned diseases and hope to offer urologists an overview of the current situation and future directions in the field of urology.

中文翻译：

---

与呕吐症状有关的预期下一代药物正在开发中。

新药开发是一项高风险的业务，但是，如果成功，它将为愿意承担这一风险的人们带来丰厚的收入。在泌尿外科领域，特别是对于下尿路症状（LUTS），最近成功的降落药物（例如米拉贝隆，肉毒杆菌毒素A和他达拉非）已引起人们对新药物开发的兴趣增加。良性前列腺增生和膀胱过度活动症候群（代表LUTS疾病）是有吸引力的目标，因为它们在泌尿外科领域的流行和市场规模很大。此外，对新研究流的认识非常重要，这不仅是因为市场规模和经济因素，而且还因为要一直为研究者保持对这些研究的持续关注。